Biotech News

Jaguar Health Reports First Quarter 2026 Financials

Jaguar Health (JAGX)jaguarhealth.gcs-web.com2026-05-21 04:47 ESTEarnings

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi ® and Canalevia ® -CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications; two crofelemer

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

JAGXJaguar Health2026-06-12 09:07:12 EST

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

JAGXJaguar Health2026-06-08 16:16:01 EST

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

JAGXJaguar Health2026-05-28 18:17:38 EST

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

JAGXJaguar Health2026-05-27 17:13:23 EST

Jaguar Health Compliant with Nasdaq Bid Price Rule

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Specialty Pharmaceuticals
Location: San Francisco, California